Clinical Trials Browser

Lung Neoplasms × Trastuzumab × Clear all

NCT02465060 2026-05-26

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT06625775 2026-04-13

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

Phase 1 Recruiting

392 enrolled

BreastGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis, Colorectal Neoplasms

NCT05143970 2026-03-20

CHANCES

Phase 1 Recruiting

27 enrolled

BreastGastrointestinalGynecologicThoracic

Breast Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Endometrial Neoplasms

NCT04285671 2026-03-10

Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer

Phase 1/2 Active not recruiting

30 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05786716 2025-12-02

DETERMINE

Phase 2/3 Recruiting

30 enrolled

DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther hematologic neoplasmThoracic

Urinary Bladder Neoplasms, Gallbladder Neoplasms, Lung Neoplasms, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Salivary Gland Neoplasms, Skin Neoplasms, Colorectal Neoplasms, Hematologic Neoplasms

NCT02393248 2023-01-06

Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)

Phase 1/2 Terminated

201 enrolled 71 charts

BreastGastrointestinalGynecologicMyeloidPlasma cellThoracic

Breast Neoplasms, Lung Neoplasms, Multiple Myeloma, Myeloproliferative Disorders, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT01679743 2019-11-15

GRN1005 for Brain Metastases From Breast or Lung Cancer

Phase 2 Withdrawn

BreastThoracic

Breast Neoplasms, Lung Neoplasms

NCT00016367 2018-10-26

Cisplatin and Gemcitabine Plus Trastuzumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Phase 2 Completed

22 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01386580 2015-01-22

An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.

Phase 1/2 Completed

84 enrolled

BreastCNSDermatologicThoracic

Brain Diseases, Brain Neoplasms, Breast Neoplasms, Central Nervous System Diseases, Glioma, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Neoplasms by Site, Neoplastic Processes, Nervous System Diseases, Nervous System Neoplasms, Pathologic Processes, Central Nervous System Neoplasms

NCT00003881 2013-06-21

Trastuzumab Plus Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer

Phase 2 Completed

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00433407 2012-10-04

T-Cell Response in Patients Receiving Trastuzumab and/or Chemotherapy for HER2-Positive Solid Tumors

Phase NA Completed

12 enrolled

BreastGenitourinaryGynecologicSarcomaThoracic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Breast Neoplasms, Male, Small Cell Lung Carcinoma